ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China · Delayed Price · Currency is CNY 10.68
+0.11 (1.04%)
At close: Feb 4, 2026
SHE:300254 Revenue
ShanXi C&Y Pharmaceutical Group Co.,LTD. had revenue of 238.48M CNY in the quarter ending September 30, 2025, with 14.82% growth. This brings the company's revenue in the last twelve months to 849.26M, up 1.56% year-over-year. In the year 2024, ShanXi C&Y Pharmaceutical Group Co.,LTD. had annual revenue of 846.61M with 5.92% growth.
Revenue (ttm)
849.26M
Revenue Growth
+1.56%
P/S Ratio
3.22
Revenue / Employee
710.09K
Employees
1,196
Market Cap
2.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 846.61M | 47.30M | 5.92% |
| Dec 31, 2023 | 799.31M | -29.69M | -3.58% |
| Jan 1, 2023 | 829.00M | -101.38M | -10.90% |
| Jan 1, 2022 | 930.37M | 82.30M | 9.70% |
| Dec 31, 2020 | 848.07M | -283.73M | -25.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Fengyuan Pharmaceutical | 4.15B |
| Hainan Huluwa Pharmaceutical Group | 1.06B |
| Enwei Pharmaceutical | 888.64M |
| Chengdu huasun technology group Inc. , LTD. | 658.28M |
| Ginwa Enterprise (Group) | 550.44M |
| Zhejiang Shapuaisi Pharmaceutical | 475.19M |
| Anhui Huangshan Capsule | 471.08M |
| Guhan Pharmaceutical Group | 351.79M |